Montz Harcus Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-3,723
Closed -$216K 57
2023
Q3
$216K Sell
3,723
-648
-15% -$39.7K 0.18% 48
2023
Q2
$280K Buy
4,371
+882
+25% +$59.1K 0.23% 42
2023
Q1
$242K Buy
3,489
+22
+0.6% +$1.55K 0.22% 45
2022
Q4
$249K Buy
3,467
+20
+0.6% +$1.51K 0.25% 44
2022
Q3
$245K Buy
3,447
+20
+0.6% +$1.45K 0.27% 40
2022
Q2
$264K Buy
3,427
+197
+6% +$15K 0.28% 41
2022
Q1
$236K Buy
+3,230
New +$217K 0.21% 48

Other funds holding BMY

Montz Harcus Wealth Management's BMY Position: Q4 2023 in Review

Montz Harcus Wealth Management sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 3,723 shares — an estimated $216K sold.

Montz Harcus Wealth Management first reported a position in BMY in Q1 2022 and held it in 7 quarters. The position peaked at $280K in Q2 2023. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

  • Montz Harcus Wealth Management reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
  • Montz Harcus Wealth Management sold 3,723 Bristol-Myers Squibb shares in Q4 2023, an estimated $216K.
  • Montz Harcus Wealth Management first reported a position in Bristol-Myers Squibb in Q1 2022 and held it in 7 quarters.
  • Montz Harcus Wealth Management's Bristol-Myers Squibb position peaked at $280K in Q2 2023.
  • 2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Montz Harcus Wealth Management's 13F filing for Q4 2023, filed 22 Jan 2024.